2-Methoxyestradiol-mediated anti-tumor effect increases osteoprotegrin expression in osteosarcoma cells

Journal of Cellular Biochemistry

Volumn 109, Issue 5, 2010, Pages 950-956

  Benedikt, Michaela B ^a   Mahlum, Eric W ^a   Shogren, Kristen L ^a   Subramaniam, Malayannan ^b   Spelsberg, Thomas C ^b   Yaszemski, Michael J ^a   Maran, Avudaiappan ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

2 Methoxyestradiol; Bone cancer; OPG. OPGL; Osteosarcoma

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 METHOXYESTRADIOL; ANTINEOPLASTIC AGENT; ESTRADIOL; MESSENGER RNA; OSTEOPROTEGERIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE CELL; BONE DEVELOPMENT; CANCER CELL; CELL CYCLE; CELL DEATH; CONTROLLED STUDY; ESTROGEN METABOLISM; HUMAN; HUMAN CELL; METABOLITE; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; WESTERN BLOTTING;

ALKALINE PHOSPHATASE; ANIMALS; CELL DEATH; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; ESTRADIOL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OSTEOBLASTS; OSTEOPROTEGERIN; OSTEOSARCOMA; PEPTIDES; RATS; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 77950454179     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22473     Document Type: Article

References (42)

1. Brown JM, Vessella RL, Kostenuik PJ, Dunstan CR, Lange PH, Corey E. 2001. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res 7:2977-2983.
2. Cicek M, Iwaniec UT, Goblirsch MJ, Vrabel A, Ruan M, Clohisy DR, Turner RR, Oursler MJ. 2007. 2-Methoxyestradiol suppresses osteolytic breast cancer tumor progression in vivo. Cancer Res 67:10106-10111.
3. Clohisy DR, Ramnaraine ML, Scully S, Qi M, Van G, Tan HL, Lacey DL. 2000. Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice. J Orthop Res 18:967-976.
4. Dobos J, Timar J, Bocsi J, Burian Z, Nagy K, Barna G, Petak I, Ladanyi A. 2004. In vitro and in vivo antitumor effect of 2-methoxyestradiol on human melanoma. Int J Cancer 112:771-776.
5. Eaton CL, Wells JM, Holen I, Croucher PI, Hamdy FC. 2004. Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. Prostate 59:304-310.
6. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR. 1998. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273:14363-14367.
7. Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L. 1994. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368:237-239.
8. Garcia GE, Wisniewski HG, Lucia MS, Arevalo N, Slaga TJ, Kraft SL, Strange R, Kumar AP. 2006. 2-Methoxyestradiol inhibits prostate tumor development in transgenic adenocarcinoma of mouse prostate: Role of tumor necrosis factor-alpha-stimulated gene 6. Clin Cancer Res 12:980-988.
9. Guise TA. 2002. The vicious cycle of bone metastases. J Musculoskelet Neuronal Interact 2:570-572.
10. Honore P, Luger NM, Sabino MA, Schwei MJ, Rogers SD, Mach DB, O'Keefe PF, Ramnaraine ML, Clohisy DR, Mantyh PW. 2000. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 6:521-528.
11. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, Komnenovic V, Kong YY, Schreiber M, Dixon SJ, Sims SM, Khokha R, Wada T, Penninger JM. 2006. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440:692-696.
12. Jung K, Lein M, Stephan C, Von Hosslin K, Semjonow A, Sinha P, Loening SA, Schnorr D. 2004. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: Diagnostic and prognostic implications. Int J Cancer 111:783-791.
13. Kang SH, Cho HT, Devi S, Zhang Z, Escuin D, Liang Z, Mao H, Brat DJ, Olson JJ, Simons JW, Lavallee TM, Giannakakou P, Van Meir EG, Shim H. 2006. Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res 66:11991-11997.
14. Khosla S. 2001. Minireview: The OPG/RANKL/RANK system. Endocrinology 142:5050-5055.
15. Lamoureux F, Richard P, Wittrant Y, Battaglia S, Pilet P, Trichet V, Blanchard F, Gouin F, Pitard B, Heymann D, Redini F. 2007. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: Blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res 67:7308-7318.
16. LaVallee TM, Zhan XH, Johnson MS, Herbstritt CJ, Swartz G, Williams MS, Hembrough WA, Green SJ, Pribluda VS. 2003. 2-methoxyestradiol upregulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res 63:468-475.
17. Lippert TH, Adlercreutz H, Berger MR, Seeger H, Elger W, Mueck AO. 2003. Effect of 2-methoxyestradiol on the growth of methyl-nitroso-urea (MNU)-induced rat mammary carcinoma. J Steroid Biochem Mol Biol 84:51-56.
18. Lipton A, Ali SM, Leitzel K, Chinchilli V, Witters L, Engle L, Holloway D, Bekker P, Dunstan CR. 2002. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 8:2306-2310.
19. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P. 2003. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3:363-375.
20. Maran A, Zhang M, Kennedy AM, Sibonga JD, Rickard DJ, Spelsberg TC, Turner RT. 2002. 2-Methoxyestradiol induces interferon gene expression and apoptosis in osteosarcoma cells. Bone 30:393-398.
21. Maran A, Gorny G, Oursler MJ, Zhang M, Shogren KL, Yaszemski MJ, Turner RT. 2006. 2-methoxyestradiol inhibits differentiation and is cytotoxic to osteoclasts. J Cell Biochem 99:425-434.
22. Maran A, Shogren KL, Benedikt M, Sarkar G, Turner RT, Yaszemski MJ. 2008. 2-methoxyestradiol-induced cell death in osteosarcoma cells is preceded by cell cycle arrest. J Cell Biochem 104:1937-1945.
23. Mizutani Y, Matsubara H, Yamamoto K, Nan Li Y, Mikami K, Okihara K, Kawauchi A, Bonavida B, Miki T. 2004. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma. Cancer 101:1794-1802.
24. Mueck AO, Seeger H, Lippert TH. 2002. Estradiol metabolism and malignant disease. Maturitas 43:1-10.
25. Mukhopadhyay T, Roth JA. 1997. Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol. Oncogene 14:379-384.
26. Mukhopadhyay T, Roth JA. 1998. Superinduction of wild-type p53 protein after 2-methoxyestradiol treatment of Ad5p53-transduced cells induces tumor cell apoptosis. Oncogene 17:241-246.
27. O'Reilly R, Cheung NK, Bowman L, Castle V, Hoffer F, Kapoor N, Kletzel M, Lindsley K, Shamberger R, Tubergen D. 1996. NCCN pediatric neuroblastoma practice guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park) 10:1813-1822.
28. Pivonka P, Zimak J, Smith DW, Gardiner BS, Dunstan CR, Sims NA, Martin TJ, Mundy GR. 2008. Model structure and control of bone remodeling: A theoretical study. Bone 43:249-263.
29. Pribluda VS, Gubish ER, Jr., Lavallee TM, Treston A, Swartz GM, Green SJ. 2000. 2-Methoxyestradiol: An endogenous antiangiogenic and antiproliferative drug candidate. Cancer Met Rev 19:173-179.
30. Qadan LR, Perez-Stable CM, Anderson C, D'Ippolito G, Herron A, Howard GA, Roos BA. 2001. 2-Methoxyestradiol induces G2/M arrest and apoptosis in prostate cancer. Biochem Biophys Res Commun 285:1259-1266.
31. Ricker JL, Chen Z, Yang XP, Pribluda VS, Swartz GM, Waes C. 2004. 2-Methoxyestradiol inhibits hypoxia-inducible factor 1a, tumor growth, and angigenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin Cancer Res 10:8665-8673.
32. Robinson JA, Harris SA, Riggs BL, Spelsberg TC. 1997. Estrogen regulation of human osteoblastic cell proliferation and differentiation. Endocrinology 138:2919-2927.
33. Schumacher G, Kataoka M, Roth JA, Mukhopadhyay T. 1999. Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin Cancer Res 5:493-499.
34. Seegers JC, Lottering ML, Grobler CJ, van Papendorp DH, Habbersett RC, Shou Y, Lehnert BE. 1997. The mammalian metabolite, 2-methoxyestradiol, affects P53 levels and apoptosis induction in transformed cells but not in normal cells. J Steroid Biochem Mol Biol 62:253-267.
35. Shogren KL, Turner RT, Yaszemski MJ, Maran A. 2007. Double-stranded RNA-dependent protein kinase is involved in 2-methoxyestradiol-mediated cell death of osteosarcoma cells. J Bone Miner Res 22:29-36.
36. Sutherland TE, Schuliga M, Harris T, Eckhardt BL, Anderson RL, Quan L, Stewart AG. 2005. 2-methoxyestradiol is an estrogen receptor agonist that supports tumor growth in murine xenograft models of breast cancer [see comment]. Clin Cancer Res 11:1722-1732.
37. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge GW, Jr. 2001. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 61:3369-3372.
38. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D. 2004. The molecular triad OPG/RANK/RANKL: Involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 15:457-475.
39. Thirunavukkarasu K, Halladay DL, Miles RR, Yang X, Galvin RJ, Chandrasekhar S, Martin TJ, Onyia JE. 2000. The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function. J Biol Chem 275:25163-25172.
40. Turner RT, Kidder LS, Zhang M, Harris SA, Westerlind KC, Maran A, Wronski TJ. 1999. Estrogen has rapid tissue-specific effects on rat bone. J Appl Physiol 86:1950-1958.
41. Ward WG, Mikaelian K, Dorey F, Mirra JM, Sassoon A, Holmes EC, Eilber FR, Eckardt JJ. 1994. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol 12:1849-1858.
42. Zhu BT, Conney AH. 1998. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res 58:2269-2277.